Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 81

1.

The state of melanoma: challenges and opportunities.

Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA.

Pigment Cell Melanoma Res. 2016 Apr 17. doi: 10.1111/pcmr.12475. [Epub ahead of print]

PMID:
27087480
2.

Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors.

Zhang G, Frederick DT, Wu L, Wei Z, Krepler C, Srinivasan S, Chae YC, Xu X, Choi H, Dimwamwa E, Ope O, Shannan B, Basu D, Zhang D, Guha M, Xiao M, Randell S, Sproesser K, Xu W, Liu J, Karakousis GC, Schuchter LM, Gangadhar TC, Amaravadi RK, Gu M, Xu C, Ghosh A, Xu W, Tian T, Zhang J, Zha S, Liu Q, Brafford P, Weeraratna A, Davies MA, Wargo JA, Avadhani NG, Lu Y, Mills GB, Altieri DC, Flaherty KT, Herlyn M.

J Clin Invest. 2016 May 2;126(5):1834-56. doi: 10.1172/JCI82661. Epub 2016 Apr 4.

PMID:
27043285
3.

sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.

Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH 3rd, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH 3rd, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA, Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT.

Nature. 2016 Apr 14;532(7598):250-4. doi: 10.1038/nature17392. Epub 2016 Apr 4.

PMID:
27042933
4.

HSP70 inhibition limits FAK-dependent invasion and enhances the response to melanoma treatment with BRAF inhibitors.

Budina-Kolomets A, Webster MR, Leu JI, Jennis M, Krepler C, Guerrini A, Kossenkov AV, Xu W, Karakousis GC, Schuchter LM, Amaravadi RK, Wu H, Yin X, Liu Q, Lu Y, Mills GB, Xu X, George DL, Weeraratna AT, Murphy ME.

Cancer Res. 2016 Mar 16. pii: canres.2137.2015. [Epub ahead of print]

PMID:
26984758
5.

Enhancing the evaluation of PI3K inhibitors through 3D melanoma models.

Shannan B, Chen Q, Watters A, Perego M, Krepler C, Thombre R, Li L, Rajan G, Peterson S, Gimotty PA, Wilson M, Nathanson KL, Gangadhar TC, Schuchter LM, Weeraratna AT, Herlyn M, Vultur A.

Pigment Cell Melanoma Res. 2016 May;29(3):317-28. doi: 10.1111/pcmr.12465. Epub 2016 Mar 21.

PMID:
26850518
6.

Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.

Krepler C, Xiao M, Sproesser K, Brafford PA, Shannan B, Beqiri M, Liu Q, Xu W, Garman B, Nathanson KL, Xu X, Karakousis GC, Mills GB, Lu Y, Ahmed TA, Poulikakos PI, Caponigro G, Boehm M, Peters M, Schuchter LM, Weeraratna AT, Herlyn M.

Clin Cancer Res. 2016 Apr 1;22(7):1592-602. doi: 10.1158/1078-0432.CCR-15-1762. Epub 2015 Dec 16.

PMID:
26673799
7.

The Wnts of change: How Wnts regulate phenotype switching in melanoma.

Webster MR, Kugel CH 3rd, Weeraratna AT.

Biochim Biophys Acta. 2015 Dec;1856(2):244-51. doi: 10.1016/j.bbcan.2015.10.002. Epub 2015 Nov 4. Review.

PMID:
26546268
8.

Genetically-defined ovarian cancer mouse models.

Morin PJ, Weeraratna AT.

J Pathol. 2016 Jan;238(2):180-4. doi: 10.1002/path.4663. Review.

PMID:
26496815
9.

PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion.

Caino MC, Ghosh JC, Chae YC, Vaira V, Rivadeneira DB, Faversani A, Rampini P, Kossenkov AV, Aird KM, Zhang R, Webster MR, Weeraratna AT, Bosari S, Languino LR, Altieri DC.

Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8638-43. doi: 10.1073/pnas.1500722112. Epub 2015 Jun 29.

10.

Novel Protein Kinase C-Mediated Control of Orai1 Function in Invasive Melanoma.

Hooper R, Zhang X, Webster M, Go C, Kedra J, Marchbank K, Gill DL, Weeraratna AT, Trebak M, Soboloff J.

Mol Cell Biol. 2015 Aug;35(16):2790-8.

11.

UV-Induced Wnt7a in the Human Skin Microenvironment Specifies the Fate of Neural Crest-Like Cells via Suppression of Notch.

Fukunaga-Kalabis M, Hristova DM, Wang JX, Li L, Heppt MV, Wei Z, Gyurdieva A, Webster MR, Oka M, Weeraratna AT, Herlyn M.

J Invest Dermatol. 2015 Jun;135(6):1521-32. doi: 10.1038/jid.2015.59. Epub 2015 Feb 23.

12.

Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells.

Webster MR, Xu M, Kinzler KA, Kaur A, Appleton J, O'Connell MP, Marchbank K, Valiga A, Dang VM, Perego M, Zhang G, Slipicevic A, Keeney F, Lehrmann E, Wood W 3rd, Becker KG, Kossenkov AV, Frederick DT, Flaherty KT, Xu X, Herlyn M, Murphy ME, Weeraratna AT.

Pigment Cell Melanoma Res. 2015 Mar;28(2):184-95. doi: 10.1111/pcmr.12330. Epub 2014 Dec 29.

13.

Meeting report from the 10th International Congress of the Society for Melanoma Research, Philadelphia, PA, November 2013.

Vultur A, O'Connell M, Webster M, Villanueva J, Herlyn D, Somasundaram R, Krepler C, Zaidi R, Patton E, Sekulic A, Jonsson G, Weeraratna AT.

Pigment Cell Melanoma Res. 2014 Jul;27(4):E1-E12. doi: 10.1111/pcmr.12240. Epub 2014 May 6. No abstract available.

PMID:
24650043
14.

Bisphosphonamidate clodronate prodrug exhibits selective cytotoxic activity against melanoma cell lines.

Webster MR, Kamat C, Connis N, Zhao M, Weeraratna AT, Rudek MA, Hann CL, Freel Meyers CL.

Mol Cancer Ther. 2014 Feb;13(2):297-306. doi: 10.1158/1535-7163.MCT-13-0315. Epub 2013 Dec 5.

15.

Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2.

O'Connell MP, Marchbank K, Webster MR, Valiga AA, Kaur A, Vultur A, Li L, Herlyn M, Villanueva J, Liu Q, Yin X, Widura S, Nelson J, Ruiz N, Camilli TC, Indig FE, Flaherty KT, Wargo JA, Frederick DT, Cooper ZA, Nair S, Amaravadi RK, Schuchter LM, Karakousis GC, Xu W, Xu X, Weeraratna AT.

Cancer Discov. 2013 Dec;3(12):1378-93. doi: 10.1158/2159-8290.CD-13-0005. Epub 2013 Oct 8.

16.

Change is in the air: the hypoxic induction of phenotype switching in melanoma.

O'Connell MP, Weeraratna AT.

J Invest Dermatol. 2013 Oct;133(10):2316-7. doi: 10.1038/jid.2013.208.

17.

Metabolic stress regulates cytoskeletal dynamics and metastasis of cancer cells.

Caino MC, Chae YC, Vaira V, Ferrero S, Nosotti M, Martin NM, Weeraratna A, O'Connell M, Jernigan D, Fatatis A, Languino LR, Bosari S, Altieri DC.

J Clin Invest. 2013 Jul;123(7):2907-20. doi: 10.1172/JCI67841. Epub 2013 Jun 10.

18.

A Wnt-er migration: the confusing role of ╬▓-catenin in melanoma metastasis.

Webster MR, Weeraratna AT.

Sci Signal. 2013 Mar 26;6(268):pe11. doi: 10.1126/scisignal.2004114. Review.

PMID:
23532332
19.

Cyclophilin D extramitochondrial signaling controls cell cycle progression and chemokine-directed cell motility.

Tavecchio M, Lisanti S, Lam A, Ghosh JC, Martin NM, O'Connell M, Weeraratna AT, Kossenkov AV, Showe LC, Altieri DC.

J Biol Chem. 2013 Feb 22;288(8):5553-61. doi: 10.1074/jbc.M112.433045. Epub 2013 Jan 9.

20.

Clonal dominance of CD133+ subset population as risk factor in tumor progression and disease recurrence of human cutaneous melanoma.

Sharma BK, Manglik V, O'Connell M, Weeraratna A, McCarron EC, Broussard JN, Divito KA, Simbulan-Rosenthal CM, Rosenthal DS, Zapas JL.

Int J Oncol. 2012 Nov;41(5):1570-6. doi: 10.3892/ijo.2012.1590. Epub 2012 Aug 17.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk